31384-08-4

Usage

Uses

Used in Pharmaceutical Industry:
2,3-dihydropyrido[4,3-d]pyridazine-1,4-dione is utilized as a therapeutic agent for the treatment of various diseases, including inflammation, pain, and cardiovascular disorders. Its mechanism of action involves the inhibition of soluble epoxide hydrolase, which can lead to the modulation of inflammatory responses and the amelioration of pain.
Used in Medicinal Chemistry Research:
DPHPPD serves as an important molecule in medicinal chemistry, where its unique structure and biological activity are harnessed to explore new avenues for drug development. Researchers are particularly interested in its potential to contribute to the creation of novel drugs targeting a range of conditions.
Used in Cancer Treatment Development:
2,3-dihydropyrido[4,3-d]pyridazine-1,4-dione is also being studied for its potential application in the development of new drugs for cancer treatment. Its ability to interact with biological targets and pathways involved in cancer progression makes it a promising candidate for further research and development in oncology.

InChI:InChI=1/C7H5N3O2/c11-6-4-1-2-8-3-5(4)7(12)10-9-6/h1-3H,(H,9,11)(H,10,12)

Upstream product

• 4664-08-8 cinchomeronic anhydride 

Downstream Products

• 38557-81-2 Pyridine-3,4-dicarboxylic acid N-oxide 
• 89663-09-2 pyrido<3,4-d>pyridazine-5,8-dione 6-oxide 
• 14490-19-8 1,4-dichloropyrido[3,4-d]pyridazine 

Relevant academic research and scientific papers

Pyrido/pyridazocyclic compound and application thereof

The invention discloses a pyrido/pyridazocyclic compound, a pharmaceutically acceptable salt and a solvent compound thereof. The invention further provides a preparation method of the compound, a composition with the compound and application of the compound for preparing medicines for treating diseases or disorders related to EED (embryonic ectoderm development) protein and/or PRC2 (polycomb repressive complex 2) protein composition action mechanisms.

PYRIDAZINE DERIVATIVES AS HEDGEHOG PATHWAY INHIBITORS

This invention relates to novel compounds. The compounds of the invention are hedgehog pathway agonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) agonists. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNALING PATHWAY INHIBITORS

This invention relates to novel compounds of formula (I). The compounds of the invention are hedgehog pathway antagonists. Specifically, the compounds of the invention are useful as Smoothened (SMO) inhibitors. The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of the Hedgehog pathway and SMO, for example cancer.

Benzocyclobutenes. Part 4. Synthesis of Benzocyclobutene-1,2-diones by Pyrolytic Methods

Oxidation of the cyclic hydrazides prepared from phthalic anhydrides in the presence of anthracene gives the corresponding Diels-Alder adducts which, on flash vacuum pyrolysis, give benzocyclobutene-1,2-dione (BBD) and its 4-chloro, 3,6- and 4,5-dichloro, 4,5-dibromo, and 4,5-dimethyl derivatives in 75-98percent yield.Cyclobuta- and cyclobuta-naphthalene-1,2-dione as well as cyclobuta- and cyclobuta-pyridine-1,2-dione have been prepared similarly; the last three of these diones are very unstable.Cyclobutanaphthalene-1,2-dione has also been made by pyrolysis of benzindene-1,2,3-trione.Attempts to make thiophen and furan analogues of BBD from appropriate anthracene adducts failed as did attempts to make tetrachloro- and tetrabromo-derivatives of BBD by the pyrolysis of tetrahalogenophthalimidosulphoximides.